Details

Autor(en) / Beteiligte

• Knopman, David S., MD
• Jack, Clifford R., MD
• Lundt, Emily S., MS
• Weigand, Stephen D., MS
• Vemuri, Prashanthi, PhD
• Lowe, Val J., MD
• Kantarci, Kejal, MD
• Gunter, Jeffrey L., PhD
• Senjem, Matthew L., MS
• Mielke, Michelle M., PhD
• Machulda, Mary M., PhD
• Roberts, Rosebud O., MBChB
• Boeve, Bradley F., MD
• Jones, David T., MD
• Petersen, Ronald C., MD, PhD

Titel

Evolution of Neurodegeneration Imaging Biomarkers from Clinically Normal to Dementia in the Alzheimer Disease Spectrum

Ist Teil von

• Neurobiology of aging, 2016-10, Vol.46, p.32-42

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Link zum Volltext

Quelle

ScienceDirect

Beschreibungen/Notizen

• Abstract The availability of antemortem biomarkers for Alzheimer’s Disease (AD) enables monitoring the evolution of neurodegenerative processes in real time. Pittsburgh compound B (PIB) positron emission tomography (PET) was used to select participants in the Mayo Clinic Study of Aging and the Mayo Alzheimer’s Disease Research Center with elevated β-amyloid, designated as “A+,” and hippocampal volume and18 fluorodeoxyglucose (FDG) positron emission tomography were used to characterize participants as having evidence of neurodegeneration (“N+”) at the baseline evaluation. There were 145 clinically normal (CN) A+ individuals, 62 persons with mild cognitive impairment (MCI) who were A+ and 20 with A+ AD dementia. Over a period of 1-6 years, MCI A+N+ individuals showed declines in medial temporal, lateral temporal, lateral parietal, and to a lesser extent, medial parietal regions for both FDG standardized uptake value ratio (SUVR) and grey matter (GM) volume that exceeded declines seen in the CN A+N+ group. The AD dementia group showed declines in the same regions on FDG SUVR and GM volume with rates that exceeded that in MCI A+N+. Expansion of regional involvement and faster rate of neurodegeneration characterizes progression in the AD pathway.